Premium
Treatment of metastatic breast cancer with aminoglutethimide
Author(s) -
Asbury R. F.,
Bakemeier R. F.,
Fölsch E.,
McCune C. S.,
Savlov E.,
Bennett J. M.
Publication year - 1981
Publication title -
cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.052
H-Index - 304
eISSN - 1097-0142
pISSN - 0008-543X
DOI - 10.1002/1097-0142(19810415)47:8<1954::aid-cncr2820470807>3.0.co;2-e
Subject(s) - medicine , aminoglutethimide , discontinuation , breast cancer , rash , metastatic breast cancer , nausea , dexamethasone , bone pain , leukopenia , cancer , oncology , gastroenterology , chemotherapy , aromatase
Seventy‐three women with metastatic breast cancer were treated with aminoglutethimide and dexamethasone. No complete responses occurred. Ten patients (16%) achieved partial responses (mean duration, 12 months). The proportions of patients responding by disease site were breast (50%), nodes (33%), skin (23%), bone (16%), lung (11%), and liver (7%). Response did not correlate with age, menopausal status, performance status, or cortisol suppression. Ninety percent of responders had had previous responses to hormonal manipulations. No responses occurred in estrogen receptor negative patients. An additional 20% of patients had disease stabilization of eight or more months (mean, 17 months). Severe bone pain was present in 47 patients and was relieved in 19. Side effects occurred in 75% but caused discontinuation of therapy in only four patients. Somnolence, nausea, rash, Cushings syndrome, and leukopenia were the most frequent side effects. Aminoglutethimide with dexamethasone is an effective hormonal treatment for metastatic breast cancer.